313 related articles for article (PubMed ID: 25528311)
21. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.
; Rodgers A; Patel A; Berwanger O; Bots M; Grimm R; Grobbee DE; Jackson R; Neal B; Neaton J; Poulter N; Rafter N; Raju PK; Reddy S; Thom S; Vander Hoorn S; Webster R
PLoS One; 2011; 6(5):e19857. PubMed ID: 21647425
[TBL] [Abstract][Full Text] [Related]
22. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials.
Selak V; Webster R; Stepien S; Bullen C; Patel A; Thom S; Arroll B; Bots ML; Brown A; Crengle S; Dorairaj P; Elley CR; Grobbee DE; Harwood M; Hillis GS; Laba TL; Neal B; Peiris D; Rafter N; Reid C; Stanton A; Tonkin A; Usherwood T; Wadham A; Rodgers A
Heart; 2019 Jan; 105(1):42-48. PubMed ID: 29954855
[TBL] [Abstract][Full Text] [Related]
23. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R;
Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247
[TBL] [Abstract][Full Text] [Related]
24. Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset.
Webster R; Bullen C; Patel A; Selak V; Stepien S; Thom S; Rodgers A
Int J Cardiol; 2017 Dec; 249():443-447. PubMed ID: 28986058
[TBL] [Abstract][Full Text] [Related]
25. Polypill-based strategy vs. usual care for secondary prevention of cardiovascular disease: a meta-analysis of randomized controlled trials.
Rivera A; Campos B; Ceolin S; Godoi A; Castanha E; Campello Jorge CA; Cardoso R
Eur J Prev Cardiol; 2023 Nov; 30(16):1828-1837. PubMed ID: 37490769
[TBL] [Abstract][Full Text] [Related]
26. Effects of time-of-day of hypertension treatment on ambulatory blood pressure and clinical characteristics of patients with type 2 diabetes.
Moyá A; Crespo JJ; Ayala DE; Ríos MT; Pousa L; Callejas PA; Salgado JL; Mojón A; Fernández JR; Hermida RC;
Chronobiol Int; 2013 Mar; 30(1-2):116-31. PubMed ID: 23181613
[TBL] [Abstract][Full Text] [Related]
27. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial.
Lee JK; Grace KA; Taylor AJ
JAMA; 2006 Dec; 296(21):2563-71. PubMed ID: 17101639
[TBL] [Abstract][Full Text] [Related]
28. Is there a BP benefit of changing the time of aspirin administration in treated hypertensive patients?
Dimitrov Y; Baguet JP; Hottelart C; Marboeuf P; Tartiere JM; Ducher M; Fauvel JP
Eur J Prev Cardiol; 2012 Aug; 19(4):706-11. PubMed ID: 21810842
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the efficacy and level of adherence for morning versus evening versus before bedtime administration of simvastatin in hypercholesterolemic patients.
Heng WK; Ng YP; Ooi GS; Habshoh J; Nurazlin J; Nor Azah MN; Hasniza H; Noriza W
Med J Malaysia; 2019 Dec; 74(6):477-482. PubMed ID: 31929472
[TBL] [Abstract][Full Text] [Related]
30. Nurse-Led, Telephone-Based, Secondary Preventive Follow-Up after Stroke or Transient Ischemic Attack Improves Blood Pressure and LDL Cholesterol: Results from the First 12 Months of the Randomized, Controlled NAILED Stroke Risk Factor Trial.
Irewall AL; Ögren J; Bergström L; Laurell K; Söderström L; Mooe T
PLoS One; 2015; 10(10):e0139997. PubMed ID: 26474055
[TBL] [Abstract][Full Text] [Related]
31. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.
Lafeber M; Grobbee DE; Spiering W; van der Graaf Y; Bots ML; Visseren FL;
Eur J Prev Cardiol; 2013 Oct; 20(5):771-8. PubMed ID: 22649123
[TBL] [Abstract][Full Text] [Related]
32. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.
Lafeber M; Spiering W; van der Graaf Y; Nathoe H; Bots ML; Grobbee DE; Visseren FL
Am Heart J; 2013 Aug; 166(2):282-289.e1. PubMed ID: 23895811
[TBL] [Abstract][Full Text] [Related]
33. Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration.
Plakogiannis R; Cohen H
Ann Pharmacother; 2007 Jan; 41(1):106-10. PubMed ID: 17200427
[TBL] [Abstract][Full Text] [Related]
34. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Malekzadeh F; Marshall T; Pourshams A; Gharravi M; Aslani A; Nateghi A; Rastegarpanah M; Khoshnia M; Semnani S; Salahi R; Thomas GN; Larijani B; Cheng KK; Malekzadeh R
Int J Clin Pract; 2010 Aug; 64(9):1220-7. PubMed ID: 20653798
[TBL] [Abstract][Full Text] [Related]
35. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
36. IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care.
Selak V; Elley CR; Crengle S; Harwood M; Doughty R; Arroll B; Bryant L; Rafter N; Hoorn SV; Wadham A; Wells S; Milne R; Jackson R; Bramley D; Rodgers A
Contemp Clin Trials; 2011 Nov; 32(6):909-15. PubMed ID: 21777702
[TBL] [Abstract][Full Text] [Related]
37. Medication Adherence With Polypill in Cardiovascular Disease and High-Risk Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Involving 7364 Participants.
Sadeghi M; Askari A; Bostan F; Heidari A; Ghasemi G; Alavi Tabatabaei G; Rafiee H; Karimi R; Roohafza H
Curr Probl Cardiol; 2024 Jan; 49(1 Pt A):102061. PubMed ID: 37640178
[TBL] [Abstract][Full Text] [Related]
38. Time-dependent effects of aspirin on blood pressure and morning platelet reactivity: a randomized cross-over trial.
Bonten TN; Snoep JD; Assendelft WJ; Zwaginga JJ; Eikenboom J; Huisman MV; Rosendaal FR; van der Bom JG
Hypertension; 2015 Apr; 65(4):743-50. PubMed ID: 25691622
[TBL] [Abstract][Full Text] [Related]
39. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
[TBL] [Abstract][Full Text] [Related]
40. Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study.
Deedwania PC; Shepherd J; Breazna A; DeMicco DA;
Diabetes Obes Metab; 2016 Jan; 18(1):56-63. PubMed ID: 26434404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
